Back to News
Market Impact: 0.2
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Source: GlobeNewswire
M&A & RestructuringManagement & Governance
Oppenheimer said it has initiated a robust process with global reach intended to benefit shareholders, suggesting a potential strategic review or transaction process. The article provides no financial terms, counterparties, timeline, or specific transaction details, limiting the ability to assess valuation or likely market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
OPY0.20
More News
- Binance CFO exits days after catastrophic $6 billion crypto hack
- Coffee giant Dutch Bros made all of its executives, including the CEO, do a two-week bootcamp where they learned how to pour drinks and run stores
- Binance CFO is leaving to ‘pursue a new venture’ after $6.3 billion hack
- Poland’s Domanski blames presidential vetoes as S&P cuts outlook to negative
- Berkshire Hathaway stock is a haven again as investors flee AI bloodbath while its own portfolio takes a hit amid reshuffling
- Berkshire Makes Record $9.6 Billion Buyback